ABSTRACT
Background Isolation of infected people and their contacts may be an effective way to control outbreaks of infectious disease, such as influenza and SARS-CoV-2. Models can provide insights into the efficacy of contact tracing, coupled with isolating or quarantining at risk people.
Methods We developed an agent-based model and simulated 15, 000 short term illnesses, with varying characteristics. For each illness we ran ten simulations on the following scenarios: (1) No tracing or isolation (None), (2) isolation of agents who have tested positive (Isolation), (3) scenario 2 coupled with minimal contact tracing and quarantine of contacts (Minimum), (4) scenario 3 with more effective contact tracing (Moderate), and (5) perfect isolation of agents who test positive and perfect tracing and quarantine of all their contacts (Maximum).
Results The median total infections of the Isolation, Minimum, Moderate and Maximum scenarios were 80%, 40%, 17% and 4% of the no intervention scenario respectively.
Conclusions Isolation of infected patients and quarantine of their contacts, even if moderately well implemented, is likely to substantially reduce the number of infections in an outbreak. Randomized controlled trials to confirm these results in the real world and to analyse the cost effectiveness of contact tracing and isolation during coronavirus and influenza outbreaks are warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding or payment received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
nathan.geffen{at}alumni.uct.ac.za, LWXMAR013{at}MyUCT.ac.za
